About GlyTherix Ltd.

About company

GlyTherix Ltd is an Australian immuno-oncology company specializing in therapeutics for solid tumors, including prostate, bladder and pancreas. GlyTherix is developing Miltuximab® for the targeted treatment of a number of cancers. At the core of the technology is a protein known as Glypican-1 (GPC-1). GPC-1 occurs in many solid tumors such as prostate, bladder, pancreatic, glioblastoma, esophageal, ovarian and brain cancers. It is not present in healthy tissue.